About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1NCT01210404

Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance

Filibuvir, a CYP3A4 inhibitor is being developed for the treatment of chronic Hepatitis C infection. Given the likelihood of co administration of filibuvir and methadone, this study will evaluate the ...

Lead sponsor: Pfizer•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Males or females, without evidence of infection with HIV,HBV or HCV, who are on chronic methadone maintenance for at least three months and at a stable dose for at least 1 week prior to study start.

Exclusion Criteria

•Evidence of chronic diseases including HIV, HBV or HCV.
•Evidence of acute or chronic liver disease.
•Treatment with prescription or nonprescription drugs other than methadone within 7 days.

Related studies

The Efficacy of Vosevi in Treating DAA-experienced Patients

NCT06180590 · Chronic Hepatitis C, Medication Reaction

Active Not Recruiting

Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong

NCT03993925 · Chronic Hepatitis C, Intravenous Drug Usage

COMPLETEDPhase 2

Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM

NCT00199719 · Chronic Hepatitis C

COMPLETEDPhase 4

Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General Hospital

NCT06922643 · Chronic Hepatitis C

Evaluating Safety and Efficacy In Hepatitis C Patients After PegIntron Pen Treatment (Study P04896)

NCT01340573 · Chronic Hepatitis C

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 7, 2011Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment12

Start dateFeb 2011

Last updatedJun 7, 2011

Condition

Chronic Hepatitis C

Locations shown

Pfizer Investigational Site

Overland Park, Kansas

Pfizer Investigational Site

Overland Park, Kansas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 7, 2011Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions